The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art

Franceschini, Davide; Rose, F. De; Cozzi, Salvatore; Franzese, Ciro; Rossi, Sabrina; Finocchiaro, Giovanna; Toschi, Luca; Santoro, Armando; Scorsetti, Marta

doi:10.1016/j.critrevonc.2020.102894

Cited by 30 publications

(18 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Definition and Biology Of Oligoprogression In Ansclcmentioning

confidence: 99%

“…The term “oligoprogression” refers to the progression of a limited number of metastatic lesions in the context of a well-controlled metastatic disease [ 2 , 5 ]. This concept is related to the wider definition of “oligometastatic” disease (“oligo” = “few”) that refers to a limited number of metastases and/or metastatic sites characterized by a more indolent behavior than a polymetastatic disease [ 5 , 6 ]. Although there is no consensus on the appropriate cut off to define the oligometastatic state, generally up to 3–5 lesions in 1–3 organs are defined in international guidelines and are commonly accepted [ 7 , 8 , 9 ].…”

Section: Definition and Biology Of Oligoprogression In Ansclcmentioning

confidence: 99%

“…Tyrosine kinase inhibitors selectively favor tumor clones that are intrinsically resistant (primary resistance) or induce changes in tumors’ phenotype (secondary resistance) [ 5 ]. Few studies are available regarding oligoprogression on ICI-treated patients.…”

Section: Definition and Biology Of Oligoprogression In Ansclcmentioning

confidence: 99%

“…Many studies have been conducted on the efficacy and safety of local ablative therapies (LAT), including radiotherapy (RT), surgery, and radiofrequency ablation (RFA), in oligometastatic and oligoprogressive aNSCLC patients [ 5 , 10 , 15 ].…”

Section: Local Ablative Therapies In Oligoprogressive Ansclcmentioning

confidence: 99%

See 3 more Smart Citations

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

Prelaj

Pircher

Massa

et al. 2021

Cancers

View full text Add to dashboard Cite

First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients’ selection, the identification of biomarkers of primary resistance to immunotherapy and the treatment strategies to overcome secondary resistance to first-line immunotherapy. Local ablative approaches are the main therapeutic strategies in oligoprogressive disease, and their role is emerging in patients treated with immunotherapy. Many therapeutic strategies can be adapted in aNSCLC patients with systemic progression to personalize the treatment approach according to re-characterization of the tumors, previous ICI response, and type of progression. This review’s aim is to highlight and discuss the current and potential therapeutic approaches beyond first-line ICI-based therapy in aNSCLC patients based on the pattern of disease progression (oligoprogression versus systemic progression).

show abstract

Section: Definition and Biology Of Oligoprogression In Ansclcmentioning

confidence: 99%

Section: Definition and Biology Of Oligoprogression In Ansclcmentioning

confidence: 99%

Section: Definition and Biology Of Oligoprogression In Ansclcmentioning

confidence: 99%

Section: Local Ablative Therapies In Oligoprogressive Ansclcmentioning

confidence: 99%

See 2 more Smart Citations

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

Prelaj

Pircher

Massa

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Altogether, the data suggest that local ablative treatment of progressive lesions in actionable mutations NSCLC patients can prolong treatment with first-line TKI without reported unacceptable excess toxicity. Moreover, despite the paucity and the heterogeneity of clinical data the use of local therapy in oligoprogressive oncogene driven NSCLC is already considered as standard clinical practice [94].…”

Section: Beyond Progression: Oligoprogression In Nsclc Patientsmentioning

confidence: 99%

Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer

Vrankar¹

2021

Lung Cancer - Modern Multidisciplinary Management

View full text Add to dashboard Cite

Since 1995, when the concept of oligometastatic non-small cell lung cancer was first described, no high-level evidence has been introduced for management of those patients subset. Data from retrospective reports and analysis and from every-day clinical practice revealed that some of the non-small cell lung cancer patients with a few metastases could benefit significantly with local radical treatment approach of primary and metastatic lesions. Recent advances in modern local treatment approaches with minimally invasive surgery and stereotactic radiotherapy, as well as introduction of immunotherapy, open new field of interest for personalized treatment of limited metastatic non-small cell lung cancer. In this report, we are summarizing limited data of case reports, retrospective studies and few randomized studies of patients with oligometastatic non-small cell lung cancer and discuss challenges of treatment in the era of molecular targeted therapy and immunotherapy.

show abstract

Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer

Chicas-Sett¹,

Zafra-Martín²

2023

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art

Cited by 30 publications

References 48 publications

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer

Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer

Contact Info

Product

Resources

About